ReviewCancer management and research2026
Hippo-YAP/TAZ Signaling in Hematological Malignancies: Molecular Mechanisms, Pathway Crosstalk and Therapeutic Potential.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hippo signaling pathway represents an evolutionarily conserved regulatory network. It plays a central role in controlling cell proliferation, apoptosis, differentiation, and tissue homeostasis. Increasing evidence indicates that dysregulation of this pathway promotes the development and progression of hematological malignancies. This includes leukemia, lymphoma, and multiple myeloma. Notably, aberrant activation of downstream effectors-Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ)-plays a central role in this process. Abnormal YAP/TAZ signaling promotes malignant cell survival, proliferation, therapeutic resistance, and disease aggressiveness through extensive crosstalk with multiple oncogenic pathways, such as Phosphatidylinositol 3-kinase (PI3K)/ Protein kinase B (AKT), Transforming growth factor-beta (TGF-β), Wnt/β-catenin, and metabolic signaling networks. Notably, the biological functions of YAP/TAZ appear to be highly context-dependent, with both oncogenic and tumor-suppressive roles reported in different hematopoietic lineages and tumor microenvironments. In this review, we summarize the molecular architecture and regulatory mechanisms of the Hippo pathway, discuss its dysregulation and functional significance in major hematological malignancies, and highlight recent advances in Hippo-targeted therapeutic strategies, including YAP/TEA domain transcription factor (TEAD) inhibitors, upstream pathway modulators, and combination treatment approaches. We further outline current challenges and future opportunities for translating Hippo-based precision therapies into clinical practice. Despite promising preclinical findings, hematological malignancy-specific clinical evidence remains limited. Future studies are required to validate Hippo-targeted therapeutic strategies and establish clinically actionable biomarkers. A deeper understanding of Hippo signaling may provide novel insights into disease biology and accelerate the development of precision medicine approaches for hematological malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.